These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1241 related articles for article (PubMed ID: 28126014)

  • 21. Adjuvant activity of CpG-ODN formulated as a liquid crystal.
    Sánchez Vallecillo MF; Ullio Gamboa GV; Palma SD; Harman MF; Chiodetti AL; Morón G; Allemandi DA; Pistoresi-Palencia MC; Maletto BA
    Biomaterials; 2014 Mar; 35(8):2529-42. PubMed ID: 24382332
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of interleukin-6 in antigen-specific mucosal immunoglobulin A induction by cationic liposomes.
    Tada R; Hidaka A; Tanazawa Y; Ohmi A; Muto S; Ogasawara M; Saito M; Ohshima A; Iwase N; Honjo E; Kiyono H; Kunisawa J; Negishi Y
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108280. PubMed ID: 34710845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants.
    McCluskie MJ; Davis HL
    Vaccine; 2000 Oct; 19(4-5):413-22. PubMed ID: 11027803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. G-quadruplex-based CpG oligodeoxynucleotide/DOTAP complex strongly stimulates immunity in CpG motif-specific and loop-length-dependent manners.
    Tu ATT; Hoshi K; Shobo M; Yamazaki T
    Nanomedicine; 2022 Feb; 40():102508. PubMed ID: 34906721
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Robust mucosal and systemic responses against HTLV-1 by delivery of multi-epitope vaccine in PLGA nanoparticles.
    Kabiri M; Sankian M; Sadri K; Tafaghodi M
    Eur J Pharm Biopharm; 2018 Dec; 133():321-330. PubMed ID: 30408519
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of salt on the physicochemical properties and immunogenicity of protein based vaccine formulated in cationic liposome.
    Yan W; Huang L
    Int J Pharm; 2009 Feb; 368(1-2):56-62. PubMed ID: 18992312
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mannose-Modified Liposome Co-Delivery of Human Papillomavirus Type 16 E7 Peptide and CpG Oligodeoxynucleotide Adjuvant Enhances Antitumor Activity Against Established Large TC-1 Grafted Tumors in Mice.
    Zhao Y; Wang H; Yang Y; Jia W; Su T; Che Y; Feng Y; Yuan X; Wang X
    Int J Nanomedicine; 2020; 15():9571-9586. PubMed ID: 33293808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein.
    Singh S; Yang G; Byrareddy SN; Barry MA; Sastry KJ
    Vaccine; 2014 Dec; 32(51):6934-6940. PubMed ID: 25444819
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intranasal administration of peptide antigens of HIV with mucosal adjuvant CpG ODN coentrapped in microparticles enhances the mucosal and systemic immune responses.
    Pun PB; Bhat AA; Mohan T; Kulkarni S; Paranjape R; Rao DN
    Int Immunopharmacol; 2009 Apr; 9(4):468-77. PubMed ID: 19291836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN.
    Tafaghodi M; Sajadi Tabassi SA; Jaafari MR
    Int J Pharm; 2006 Aug; 319(1-2):37-43. PubMed ID: 16701972
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Carbonate Apatite Nanoparticles Act as Potent Vaccine Adjuvant Delivery Vehicles by Enhancing Cytokine Production Induced by Encapsulated Cytosine-Phosphate-Guanine Oligodeoxynucleotides.
    Takahashi H; Misato K; Aoshi T; Yamamoto Y; Kubota Y; Wu X; Kuroda E; Ishii KJ; Yamamoto H; Yoshioka Y
    Front Immunol; 2018; 9():783. PubMed ID: 29720976
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunostimulatory Properties of Lipid Modified CpG Oligonucleotides.
    Yu C; An M; Li M; Liu H
    Mol Pharm; 2017 Aug; 14(8):2815-2823. PubMed ID: 28686452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Orally administered OVA/CpG-ODN induces specific mucosal and systemic immune response in young and aged mice.
    Alignani D; Maletto B; Liscovsky M; Rópolo A; Morón G; Pistoresi-Palencia MC
    J Leukoc Biol; 2005 Jun; 77(6):898-905. PubMed ID: 15758079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conjugation of lipid and CpG-containing oligonucleotide yields an efficient method for liposome incorporation.
    Andrews CD; Provoda CJ; Ott G; Lee KD
    Bioconjug Chem; 2011 Jul; 22(7):1279-86. PubMed ID: 21612239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice.
    McCluskie MJ; Davis HL
    J Immunol; 1998 Nov; 161(9):4463-6. PubMed ID: 9794366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
    Joseph A; Itskovitz-Cooper N; Samira S; Flasterstein O; Eliyahu H; Simberg D; Goldwaser I; Barenholz Y; Kedar E
    Vaccine; 2006 May; 24(18):3990-4006. PubMed ID: 16516356
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of nasal application of CpG oligodeoxynucleotide as a mucosal adjuvant.
    Kodama S; Abe N; Hirano T; Suzuki M
    Laryngoscope; 2006 Feb; 116(2):331-5. PubMed ID: 16467729
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liposomal SLA co-incorporated with PO CpG ODNs or PS CpG ODNs induce the same protection against the murine model of leishmaniasis.
    Shargh VH; Jaafari MR; Khamesipour A; Jaafari I; Jalali SA; Abbasi A; Badiee A
    Vaccine; 2012 Jun; 30(26):3957-64. PubMed ID: 22465747
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intranasal immunization using biphasic lipid vesicles as delivery systems for OmlA bacterial protein antigen and CpG oligonucleotides adjuvant in a mouse model.
    Alcón VL; Baca-Estrada M; Vega-López MA; Willson P; Babiuk LA; Kumar P; Foldvari M
    J Pharm Pharmacol; 2005 Aug; 57(8):955-62. PubMed ID: 16102250
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunostimulatory sequence oligdeoxynucleotide/cholera toxin B conjugate: a novel allergen-independent intranasal vaccine for allergic rhinitis.
    Won TB; Quan SH; Kim DY; Rhee CS; Lee CH
    Ann Allergy Asthma Immunol; 2009 Apr; 102(4):314-22. PubMed ID: 19441603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 63.